Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 5

Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability

Authors Andre R Brunoni, Renerio Fraguas Jr, Felipe Fregni

Published Date November 2009 Volume 2009:5 Pages 897—910

DOI http://dx.doi.org/10.2147/TCRM.S5751

Published 17 November 2009

Andre R Brunoni1, Renerio Fraguas Jr1, Felipe Fregni2

1Department and Institute of Psychiatry, University of Sao Paulo, Brazil; 2Laboratory of Neuromodulation, Spaulding Rehabilitation Center, Harvard Medical School and Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA

Background: Use of antidepressants is the gold standard therapy for major depression. However, despite the large number of commercially available antidepressant drugs there are several differences among them in efficacy, tolerability, and cost-effectiveness. In addition the optimal augmentation strategy is still not clear when dealing with treatment-resistant depression, a condition that affects 15% to 40% of depressed patients.

Methods: We therefore reviewed the main characteristics of these drugs regarding their efficacy, tolerability, side effects and cost-effectiveness, by accessing all meta-analyses and systematic reviews published from 2004 to 2009. In addition, we reviewed the augmentation strategy of associated antidepressants with neurostimulation therapies (such as transcranial magnetic stimulation [TMS] and transcranial direct current stimulation [tDCS]). A search was undertaken in MEDLINE, Web of Science, Cochrane, and Scielo databases. We included: 21 meta-analyses of antidepressant trials, 15 neurostimulation clinical trials and 8 studies of pharmacoeconomics. We then performed a comprehensive review on these articles.

Results and Conclusion: Although recent meta-analyses suggest sertraline and escitalopram might have increased efficacy/tolerability, other studies and large pragmatic trials have not found these to be superior to other antidepressant drugs. Also, we did not identify any superior drug in terms of cost-effectiveness due to the different designs observed among pharmacoecomics studies. Side effects such as sexual dysfunction, gastrointestinal problems and weight gain were common causes of discontinuation. Tolerability was an important issue for novel neurostimulation interventions, such as TMS and tDCS. These therapies might be interesting augmentation strategies, considering their benign profile of side effects, if proper safety parameters are adopted.

Keywords: acute depressive episode, pharmacological interventions, combined interventions

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008

An analysis of the Bateson Review of research using nonhuman primates

Greek R, Hansen LA, Menache A

Medicolegal and Bioethics 2011, 1:3-22

Published Date: 6 December 2011

A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting

Zhang L, Zhu WW, Yang CF, Guo HX, Yu AH, Ji JB, Gao Y, Sun M, Zhai GX

International Journal of Nanomedicine 2012, 7:151-162

Published Date: 9 January 2012

Alcohol and prescription drug safety in older adults

Zanjani F, Hoogland AI, Downer BG

Drug, Healthcare and Patient Safety 2013, 5:13-27

Published Date: 25 February 2013

Clinical use of anti-TNF therapy and increased risk of infections

Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS

Drug, Healthcare and Patient Safety 2013, 5:79-99

Published Date: 28 March 2013

The Gay Men Sex Studies: prevalence of sexual dysfunctions in Belgian HIV+ gay men

Vansintejan J, Janssen J, Van De Vijver E, Vandevoorde J, Devroey D

HIV/AIDS - Research and Palliative Care 2013, 5:89-96

Published Date: 26 April 2013